Frontlight ResearchEarly access
Taking peoplePhase 3
Tests JNJ-77242113 in adults with moderate to severe plaque psoriasis
Tests JNJ-77242113 against a placebo in adults with moderate to severe plaque psoriasis.
Key facts
- Who runs it
- Janssen - Cilag International
- Where
- Bialystok, Cracow, Elblag, Krakow, Lodz, Osielsko (Bydgoszcz), Poznan, Warsaw, and Wroclaw, PolandSee the 16 sitesAlso in 5 other countries, 47 sites
- Trial code
- Registry title
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 320 people, planned
- Started
- 18 Jan 2024
- Expected to end
- 15 Jun 2027
- Type of study
- Interventional
- Record updated
- 16 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe plaque psoriasis. It tests JNJ-77242113 against a placebo and against deucravacitinib.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Plaque psoriasis, with or without psoriatic arthritis (PsA), diagnosed at least 26 weeks before the first study treatment. Skin area affected (BSA) 10% or more, PASI score 12 or more, and IGA score 3 or more, at screening and at baseline.
Main reasons for not taking part
- A form of psoriasis that is not plaque psoriasis
- Psoriasis caused by a drug right now
- Severe, worsening or uncontrolled kidney, liver, heart, blood vessel, lung, stomach and bowel, hormone, nerve, blood, rheumatic, mental health or metabolic problems
- Known allergy or intolerance to JNJ-77242113, deucravacitinib or any ingredient of the study treatment
- Major surgery within 8 weeks before screening, not fully recovered, or planned during the trial
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- ≥18 years of age at the screening visit
- Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention
- Total BSA ≥10% at screening and baseline
- Total PASI ≥12 at screening and baseline
- Total IGA ≥3 at screening and baseline
Who cannot take part
- Current drug-induced psoriasis
- Major surgical procedure, within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
- A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention
- Nonplaque form of psoriasis
Where in Poland
Also in 5 other countries, 47 sites
- Osteo Medic s.c. Artur Racewicz Jerzy SupronikBialystok, PolandNo longer taking part
- Specderm Poznanska sp.j.Bialystok, PolandNo longer taking part
- Centrum Medyczne Dr Rajzer Sp. z o.o.Cracow, PolandNo longer taking part
- Promed P.Lach R.Glowacki Sp. j.Cracow, PolandNo longer taking part
- Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p.Elblag, PolandNo longer taking part
- Specjalistyczny Gabinet Dermatologiczny Aplikacyjno Badawczy Marek Brzewski Paweł Brzewski s.c.Krakow, PolandNo longer taking part
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.Lodz, PolandNo longer taking part
- DERMED Centrum Medyczne Sp. z o.o.Lodz, PolandNo longer taking part
- DermoDent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski s.cOsielsko (Bydgoszcz), PolandNo longer taking part
- Clinical Research Center Sp z o o Medic R Sp kPoznan, PolandNo longer taking part
- Solumed Centrum Medyczne Sp. z o.o.Poznan, PolandNo longer taking part
- Dorota Bystrzanowska High-Med. Przychodnia SpecjalistycznaWarsaw, PolandNo longer taking part
- Klinika Ambroziak Sp. z o.o.Warsaw, PolandNo longer taking part
- Centrum Medyczne OporowWroclaw, PolandNo longer taking part
- dermMedica Sp. z o.oWroclaw, PolandNo longer taking part
- WroMedica I Bielicka A Strzalkowska s cWroclaw, PolandNo longer taking part
About the trial
What the trial wants to find out
To evaluate the efficacy of JNJ-77242113 compared with placebo in participants with moderate to severe plaque psoriasis.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Plain-language title
- Tests JNJ-77242113 in adults with moderate to severe plaque psoriasisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 16 July 2026